APOGEE THERAPEUTICS, INC. (APGE)
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
📈 **POSITIVE** • High confidence analysis (82%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (91%) **Content type:** Clinical